GT Biopharma(GTBP.US)

Last Updated 19:00:00 ET
longbridge loading

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

PR Newswire·
US
GTBP
+0.84%
US
XBI
+3.32%
US
LABU
+10.02%
PR Newswire·
US
GTBP
+0.84%
US
XBI
+3.32%
US
LABU
+10.02%

GT Biopharma reports Q1 results

businessinsider·
US
GTBP
+0.84%
US
BIB
+3.26%
US
IBB
+1.75%
businessinsider·
US
GTBP
+0.84%
US
BIB
+3.26%
US
IBB
+1.75%

GTBP Q1'26 Earnings: EPS estimate is (0.08) USD

TradingView·
US
GTBP
+0.84%
US
PBE
+0.89%
US
XBI
+3.32%
TradingView·
US
GTBP
+0.84%
US
PBE
+0.89%
US
XBI
+3.32%

Hot pre-market trades in US stocks: GT Biopharma pre-market down 8.93%; Everspin Tech pre-market down 8.86%

Price Alert·
US
GTBP
+0.84%
US
MRAM
-7.85%
Price Alert·
US
GTBP
+0.84%
US
MRAM
-7.85%

First Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid Tumors

Baystreet·
US
GTBP
+0.84%
US
SBIO
+2.76%
US
LABU
+10.02%
Baystreet·
US
GTBP
+0.84%
US
SBIO
+2.76%
US
LABU
+10.02%

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

benzinga_article·
US
GTBP
+0.84%
US
SBIO
+2.76%
US
IBBQ
+1.65%
benzinga_article·
US
GTBP
+0.84%
US
SBIO
+2.76%
US
IBBQ
+1.65%

GT Biopharma shares are trading higher after the company announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550.

benzinga_article·
US
GTBP
+0.84%
US
IBB
+1.75%
US
PBE
+0.89%
benzinga_article·
US
GTBP
+0.84%
US
IBB
+1.75%
US
PBE
+0.89%
© 2026 Longbridge｜Disclaimer